Curasight AS (XSAT:CURAS) EBIT: kr-64.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:CURAS Curasight AS XSAT:CURAS
24 GF Score
Price kr15.70
! 2 Warning Signs
View Full Analysis

What is Curasight AS EBIT?

Curasight AS XSAT:CURAS -6.27% 24 EBIT is kr-64.00 Mil as of Mar. 2026. GuruFocus rates XSAT:CURAS with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Curasight AS's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-15.28 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-64.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Curasight AS's annualized ROC % for the quarter that ended in Mar. 2026 was -302.83%. Curasight AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Curasight AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -8.56%.

Curasight AS  (XSAT:CURAS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Curasight AS's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-61.108 * ( 1 - 8.23% )/( (31.15 + 5.887)/ 2 )
=-56.0788116/18.5185
=-302.83 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=50.055 - 7.059 - ( 35.912 - max(0, 32.119 - 43.965+35.912))
=31.15

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=36.246 - 29.354 - ( 22.089 - max(0, 29.354 - 30.359+22.089))
=5.887

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Curasight AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-61.112/( ( (0 + max(-26.619, 0)) + (0 + max(-22.48, 0)) )/ 2 )
=-61.112/( ( 0 + 0 )/ 2 )
=-61.112/0
= %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 5.5) - (7.059 + 0 + 25.06)
=-26.619

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 6.874) - (29.354 + 0 + 0)
=-22.48

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Curasight AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-63.995/747.274
=-8.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curasight AS EBIT Related Terms

Curasight AS EBIT Historical Data

* Premium members only.

The historical data trend for Curasight AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curasight AS EBIT Chart

Curasight AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -11.40 -18.96 -33.21 -40.10 -55.55

Curasight AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.21 -19.01 -13.55 -16.16 -15.28

XSAT:CURAS vs VRTX, REGN, RVMD: EBIT Comparison

For the Biotechnology subindustry, Curasight AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curasight AS EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curasight AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Curasight AS's EV-to-EBIT falls into.


XSAT:CURAS
24GF Score
Curasight AS XSAT:CURAS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curasight AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-64.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-64.00 Mil mean?
Curasight AS (XSAT:CURAS) has a EBIT of kr-64.00 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Curasight AS.
Is Curasight AS's EBIT too high?
Curasight AS's current EBIT is kr-64.00 Mil. Overall, Curasight AS has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Curasight AS's EBIT compare to VRTX and REGN?
Curasight AS's EBIT of kr-64.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Curasight AS. Curasight AS's current EBIT is kr-64.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curasight AS stock overvalued right now?
Curasight AS (XSAT:CURAS) has a current EBIT of kr-64.00 Mil. The current EBIT is kr-64.00 Mil. Curasight AS's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Curasight AS (XSAT:CURAS), the current EBIT is kr-64.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curasight AS Business Description

Other Exchanges CUS:Germany
Address Ole Maaloes Vej 3, Kobenhavn N, Kobenhavn, DNK, DK-2200
Curasight AS is a clinical-stage radiopharmaceutical company based in Copenhagen, Denmark, developing uTREAT, a first-in-class uPAR-targeted radioligand therapy (RLT) platform designed to treat aggressive solid tumors. The Company is focused on advancing its diagnostic and therapeutic platforms through key clinical milestones.
24GF Score

Get the complete analysis for XSAT:CURAS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr15.70
Price